Immune response study for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how your immune system responds to triple-negative breast cancer. It will test your blood or tissue to learn more about your body's natural defenses against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with triple-negative breast cancer (TNBC).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for “biomarkers,” or tumor clues, that may help predict who benefits from checkpoint inhibitor immunotherapy in triple-negative breast cancer. It may help doctors choose the right treatment approach in the future, especially when chemotherapy is planned.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This study is testing a research tool that may help doctors choose the best treatment for people with advanced triple-negative breast cancer. You will have a biopsy and blood draw to help see how the tool works.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This study helps doctors predict which patients will respond best to immunochemotherapy (a combination of immune-boosting and chemotherapy drugs) for early-stage triple-negative breast cancer. By understanding your tumor better before treatment, doctors may be able to personalize your care plan.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.